NSG 552 Exam 1 Antipsychotics 2026 – 90+ Practice Questions on Schizophrenia, Typical vs Atypical Antipsychotics, EPS & Clozapine Monitoring

This comprehensive NSG 552 Exam 1 Antipsychotics study guide contains over 90 high-yield practice questions and answers covering the neurobiology of schizophrenia, dopamine pathways, antipsychotic pharmacology, extrapyramidal symptom (EPS) management, and evidence-based prescribing principles essential for advanced psychiatric nursing practice. Designed for graduate nursing students and advanced practice providers, this resource transforms complex psychopharmacology concepts into an active recall format that strengthens diagnostic reasoning, enhances medication safety awareness, and improves performance on psychiatric nursing examinations and PMHNP certification assessments. The material integrates receptor pharmacology, adverse effect recognition, therapeutic monitoring, and clinical decision-making strategies commonly emphasized in psychopharmacology coursework and advanced psychiatric practice. The guide begins with an in-depth review of the four major dopaminergic pathways implicated in schizophrenia and antipsychotic therapy, including the mesolimbic, mesocortical, nigrostriatal, and tuberoinfundibular systems. Students will strengthen their understanding of how alterations within these pathways contribute to positive symptoms such as hallucinations and delusions, negative symptoms including avolition and anhedonia, cognitive dysfunction, extrapyramidal adverse effects, and hyperprolactinemia. These foundational concepts provide a framework for understanding the therapeutic effects and adverse outcomes associated with dopamine receptor blockade. Extensive coverage of schizophrenia symptomatology explores the distinction between positive and negative symptoms and their influence on treatment selection. Learners will review evidence supporting second-generation antipsychotics (SGAs) as first-line therapy while comparing their effectiveness against first-generation antipsychotics (FGAs). Topics include the differential impact of these agents on symptom domains, risks associated with antipsychotic polypharmacy, and the clinical consequences of excessive dopamine antagonism, including increased rates of metabolic complications, extrapyramidal symptoms, rehospitalization, and sudden cardiac death. The resource provides detailed examination of typical and atypical antipsychotic classifications, emphasizing receptor profiles, mechanisms of action, and medication-specific considerations. Students will review commonly prescribed FGAs including haloperidol, chlorpromazine, fluphenazine, perphenazine, and thiothixene, alongside SGAs such as aripiprazole, risperidone, olanzapine, quetiapine, ziprasidone, lurasidone, paliperidone, and clozapine. The guide highlights differences in efficacy, neurological adverse effects, metabolic burden, and therapeutic applications, enabling learners to select evidence-based treatment options tailored to individual patient needs. Comprehensive review of extrapyramidal symptoms and movement disorders strengthens clinical recognition and management skills. Learners will differentiate acute dystonia, akathisia, pseudoparkinsonism, and tardive dyskinesia through characteristic presentations, timelines of onset, and recommended interventions. First-line treatment approaches, including benztropine for dystonia and propranolol for akathisia, are explored alongside the pathophysiology underlying dopamine blockade within the nigrostriatal pathway. Special emphasis is placed on the use of the Abnormal Involuntary Movement Scale (AIMS) for baseline and ongoing screening, as well as FDA-approved therapies such as valbenazine and deutetrabenazine for tardive dyskinesia management. The guide further examines serious antipsychotic-related complications, including Neuroleptic Malignant Syndrome (NMS), a life-threatening emergency characterized by fever, lead-pipe rigidity, autonomic instability, and altered mental status. Students will review distinguishing features, risk factors, and clinical priorities associated with early recognition and intervention to reduce morbidity and mortality. Clozapine pharmacology and monitoring receive extensive attention due to their importance in advanced psychiatric practice. Students will explore clozapine's unique efficacy in treatment-resistant schizophrenia and suicide prevention, along with the requirements of the Clozapine REMS program. Topics include absolute neutrophil count (ANC) monitoring schedules, agranulocytosis risk, seizure management strategies, metabolic monitoring parameters, and indications for transitioning patients to clozapine when conventional therapies fail. Additional content reviews long-acting injectable antipsychotics, prolactin-related adverse effects, weight-neutral treatment options, black box warnings regarding dementia-related psychosis, rebound psychosis associated with abrupt discontinuation, and considerations for selecting agents in patients with obesity or medication nonadherence. These concepts reinforce safe prescribing practices and strengthen confidence in managing complex psychiatric presentations. This study guide is particularly valuable for Psychiatric Mental Health Nurse Practitioner (PMHNP) students, Master of Science in Nursing (MSN) students, Doctor of Nursing Practice (DNP) students, psychiatric nursing students, advanced practice registered nurses, physician assistant students specializing in behavioral health, psychiatry residents, nurse practitioner certification candidates, and healthcare professionals seeking a focused review of antipsychotic pharmacotherapy and schizophrenia management. The content aligns with established evidence-based standards and authoritative references, including: Stahl, S. M. (2024). Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (6th ed.). Cambridge University Press. Stahl, S. M. (2024). Stahl's Essential Psychopharmacology Prescriber's Guide (8th ed.). Cambridge University Press. American Psychiatric Association. (2020). Practice Guideline for the Treatment of Patients With Schizophrenia. Townsend, M. C., & Morgan, K. I. (2024). Psychiatric Mental Health Nursing: Concepts of Care in Evidence-Based Practice (11th ed.). F.A. Davis. Sadock, B. J., Sadock, V. A., & Ruiz, P. (2022). Kaplan & Sadock's Synopsis of Psychiatry (12th ed.). Wolters Kluwer. National Institute for Health and Care Excellence (NICE). Current recommendations for the assessment and management of psychosis and schizophrenia in adults. Designed as both an intensive examination review and a practical psychopharmacology companion, this study guide promotes active learning, strengthens prescribing confidence, enhances medication safety awareness, and prepares learners to integrate evidence-based antipsychotic therapy into advanced psychiatric nursing practice. Keywords: NSG 552, NSG 552 Exam 1, Antipsychotics, Psychopharmacology, Schizophrenia, Schizophrenia pharmacology, Dopamine pathways, Mesolimbic pathway, Mesocortical pathway, Nigrostriatal pathway, Tuberoinfundibular pathway, Positive symptoms, Negative symptoms, Typical antipsychotics, First-generation antipsychotics, FGAs, Atypical antipsychotics, Second-generation antipsychotics, SGAs, Haloperidol, Chlorpromazine, Fluphenazine, Perphenazine, Aripiprazole, Risperidone, Olanzapine, Quetiapine, Ziprasidone, Lurasidone, Paliperidone, Clozapine, Extrapyramidal symptoms, EPS, Acute dystonia, Akathisia, Pseudoparkinsonism, Tardive dyskinesia, AIMS scale, Valbenazine, Deutetrabenazine, Neuroleptic malignant syndrome, NMS, Hyperprolactinemia, Agranulocytosis, Clozapine REMS, ANC monitoring, Long-acting injectable antipsychotics, Metabolic syndrome, Weight gain, QT prolongation, Suicide prevention, Treatment-resistant schizophrenia, PMHNP exam preparation, Psychiatric nursing review, Advanced psychopharmacology, Nurse practitioner certification review